Special Issue

Personalized Medicine in Brain Tumors

Message from the Guest Editors

Brain tumors are a heterogeneous group including, among others, gliomas, neuronal tumors, embryonal tumors, meningiomas, other mesenchymal tumors, lymphomas, and sellar tumors. An increasing body of evidence points towards the biological heterogeneity of brain tumors, both at the cellular and molecular level. Accordingly, the upcoming 2021 WHO classification will expand an integrated histological-molecular approach, in which molecular data have a key role in establishing the correct diagnosis. From a therapeutic viewpoint, in some histologies, like lower-grade gliomas and medulloblastomas, such refined diagnosis has led to effective treatments. However, in other tumors, e.g., GBM, notwithstanding the huge advances in cellular and molecular profiling, novel therapeutics have failed to improve prognosis, which remains dismal. These issues foster an increased effort towards a personalized approach to brain tumors, in which a tailored treatment is administered based on the clinical, radiological, histopathological, biological, and molecular features of the single tumor.

Guest Editors

Prof. Roberto Pallini

Department of Neurosurgery, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Rome, Italy

Dr. Quintino Giorgio D'Alessandris

Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Largo A. Gemelli, 8, 00168 Rome, Italy

Deadline for manuscript submissions

closed (25 July 2023)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/76022

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

